Special Edition: Meeting demand for viral vectors

VIVEbiotech looks to overcome challenges related to LVV production

By Jane Byrne contact

- Last updated on GMT

Event inaugurating the new plant in Spain in June © VIVEbiotech
Event inaugurating the new plant in Spain in June © VIVEbiotech

Related tags: Viral vector, lentiviral vector

VIVEbiotech, a lentivirus-specialized contract development and manufacturing organization (CDMO) that produces vectors for projects from early-stage to GMP production, is working on enhancing intrinsic lentivirus characteristics and streamlining the process.

The Spanish company says it teams are dedicated to making the manufacturing process more cost-effective, scalable and regulatory compliant.

In June this year, the CDMO opened a new manufacturing plant, with the objective of significantly increasing its production capacities by 400% and delivering its lentiviral vectors (LVVs) on a commercial scale to meet the growing demand for those vectors from the cell and gene therapy (CGT) sector. The San Sebastian plant also sees the installation of the largest bioreactor currently available on the global market, enabling batch size to be increased more than 60 times. The new facility also contains seven cleanrooms specifically set up for viral vector production.

“Along with the increased batch size, facility configuration has been designed in a much more flexible manner. In this new site, we have focused not only in increasing the GMP capacity but also very importantly the initial R&D and process optimization phases capabilities," ​VIVEbiotech CEO, Dr Gurutz Linazasoro, told BioPharma-Reporter.

The CDMO has contributed to the development and manufacture of LVVs for more than 30 international projects of 20 different customers for different applications that range from immune-oncology and rare diseases among others, both ex vivo and in vivo use.

“For VIVEbiotech the main objective is that these therapies using LVVs reach the largest number of patients as possible. So it is essential that the LVV production processes are more cost-effective with a titer increase and an enhanced purity that has a great impact on the functionality of lentiviral vectors to transduce the target cell, that they target the cells in a more specific manner so as to have a greater impact in terms of the required multiplicity of infection (MOI).” ​continued the CEO.

The high titer increases transduction efficiency, and the high purity reduces cytotoxicity.

Pseudotyping strategies 

More than a third of VIVEbiotech's budget is invested in R&D and USP/DSP optimization, and those teams are also working on, among other aspects, the development of different pseudotyping strategies, with a strong focus on optimizing purity.

Studies have demonstrated the great impact that a different pseudotyping approach can have on the final functionality of target cells. Commentators says pseudotyping is, and will continue to be, one of the major vector characteristics to be considered on the road to improving LVVs.

R&D projects 

What other challenges in viral vector production remain and what is VIVE doing to overcome them?

“It is not only a matter of increasing particles production but also that these particles are more functional. VIVEbiotech is actively working on a dedicated project related to this," ​said Linazasoro.

Moreover, accurate enumeration of total particle count of gene therapy vectors is critical in order to minimize the risk of adverse immune response or other negative outcomes when treating patients.

In that context, VIVE says it has R&D projects focused on rapid particles counting, along with electronic microscopy analysis and lipidomic characterization work, said the CEO.

VIVE is to increase its staff to 85 employees by the end of 2021 to support the production of LVVs. The US is the CDMO’s main market, representing 70% of its customer base, with companies in Europe and Asia accounting for the remaining 30%.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us

Products

View more

Webinars